Aneurysmal subarachnoid hemorrhage remains one of the most catastrophic cerebrovascular emergencies in modern neurocritical care. Although early surgical or endovascular repair successfully secures the ruptured intracranial aneurysm, secondary complications frequently dictate long-term neurological recovery. Delayed cerebral ischemia and arterial narrowing represent primary drivers of poor patient outcomes and prolonged hospital stays. Consequently, neurointensivists continuously explore neuroprotective interventions that attenuate arterial constriction and preserve downstream microvascular perfusion. Preclinical research has consistently identified divalent cations as critical modulators of cerebrovascular tone and excitotoxicity. In particular, clinicians have extensively evaluated magnesium for cerebral vasospasm due to its NMDA-receptor antagonism and potent calcium channel-blocking capabilities. Despite encouraging animal data, translating these therapeutic mechanisms into reproducible clinical benefits has challenged researchers for decades. Therefore, investigators designed a rigorous randomized clinical trial to determine whether early, targeted maintenance of serum magnesium could mitigate arterial spasms and improve functional outcomes.

Evaluating Magnesium for Cerebral Vasospasm in Acute aSAH

To address persistent clinical uncertainties, researchers executed a prospective, multicenter, single-blind randomized controlled trial across four academic neurocritical care centers in South Korea. Between 2019 and 2024, investigators enrolled 121 adult patients presenting with acute aneurysmal subarachnoid hemorrhage. Importantly, clinicians initiated protocol therapy within an aggressive six-hour window following emergency hospital admission. The clinical team randomized participants to receive either continuous intravenous magnesium sulfate infusions or standard isotonic placebo. Furthermore, clinicians systematically monitored daily laboratory panels to titrate magnesium infusions toward a targeted serum concentration of 2.0 to 3.0 mg/dL throughout a 14-day intervention window.

The primary study endpoint examined the overall incidence of cerebral vasospasm confirmed through routine transcranial Doppler ultrasonography. Additionally, investigators collected comprehensive secondary outcomes, including delayed cerebral ischemia, length of intensive care stay, total hospital duration, and 30-day functional recovery via the modified Rankin Scale. By enforcing early therapeutic administration and precise serum level monitoring, the trial aimed to eliminate common confounding factors observed in previous studies. Ultimately, the trial evaluated whether sustained normo-to-hypermagnesemia creates a stable physiological shield against delayed arterial narrowing.

Hemodynamic Impact and Transcranial Doppler Surveillance

Transcranial Doppler ultrasound provides an essential, non-invasive bedside tool for tracking cerebral blood flow velocities following aneurysmal rupture. In this trial, serial Doppler examinations revealed noteworthy hemodynamic differences between the two study arms. Specifically, patients receiving intravenous magnesium exhibited significantly lower mean flow velocities within the middle cerebral arteries between hospital days 4 and 9. Moreover, the magnesium cohort demonstrated lower Lindegaard ratios during this identical critical window. Because the Lindegaard ratio compares intracranial velocities to extracranial internal carotid artery flow, it reliably differentiates true arterial vasospasm from systemic hyperdynamic flow or therapeutic hyperemia.

Consequently, these physiological observations confirm that early magnesium administration exerts measurable vasodilatory effects during the peak temporal window of vasospasm vulnerability. Nevertheless, the total incidence of transcranial Doppler-defined vasospasm did not differ significantly between the magnesium and control groups over the full study period. Thus, while magnesium attenuated the absolute velocity elevations and reduced overall hemodynamic severity, it failed to eliminate arterial narrowing entirely. Critical care teams must recognize that hemodynamic modulation does not always translate into complete vascular protection.

Clinical Outcomes and Delayed Cerebral Ischemia Rates

Beyond transcranial Doppler waveforms, the critical measure of any neurovascular therapy lies in preventing permanent tissue infarction and functional disability. In this trial, the reduction in hemodynamic velocity did not translate into a statistically significant decrease in delayed cerebral ischemia. Similarly, patients in the magnesium cohort experienced intensive care and overall hospital lengths of stay comparable to those in the placebo group. Furthermore, functional evaluations at 30 days using the modified Rankin Scale showed no significant divergence between the treatment arms.

Safety analyses offered reassuring findings, as serious adverse events, including symptomatic bradycardia, severe hypotension, and respiratory depression, did not differ between cohorts. However, exploratory multivariable analyses uncovered an intriguing physiological signal. Specifically, maintaining a median serum magnesium concentration greater than or equal to 2.5 mg/dL during the initial 14 hospital days was independently associated with significantly lower risks of both cerebral vasospasm and delayed cerebral ischemia. Consequently, while general protocolized infusion within the 2.0 to 3.0 mg/dL target failed to improve primary clinical endpoints, higher-tier serum concentrations might confer selective neurovascular benefits. Researchers must investigate these exploratory observations in prospective dose-optimization studies before clinicians change established bedside regimens.

Contextualizing Results with Historic SAH Trials

The findings from this trial align closely with historical landmark investigations that explored magnesium therapy for acute cerebrovascular injury. For example, the large-scale MASH-2 trial evaluated over 1,200 patients and found that routine intravenous magnesium sulfate did not improve functional outcomes after aneurysmal subarachnoid hemorrhage. Similarly, the Hong Kong-based IMASH trial demonstrated that targeting twice baseline serum magnesium levels failed to reduce clinical vasospasm or improve six-month recovery scores. Therefore, contemporary evidence consistently highlights a recurring paradox in neurovascular research: effective preclinical and sonographic vasodilation often fails to prevent clinical infarction.

Several physiological mechanisms explain this persistent therapeutic disconnect. First, delayed cerebral ischemia involves complex, multifactorial pathways, including cortical spreading depolarization, microvascular thrombosis, neuroinflammation, and blood-brain barrier breakdown. Consequently, merely dilating proximal conducting arteries cannot prevent downstream microcirculatory failure or ischemic cell death. In addition, peripheral intravenous infusions achieve variable penetration across the injured blood-brain barrier, which may limit cerebral spinal fluid magnesium concentrations. Thus, historical and contemporary trials reinforce that macroscopic vessel caliber represents only one component of delayed neurovascular injury. Clinicians cannot rely solely on smooth muscle relaxation to secure meaningful neurological recovery.

Evidence-Based Protocols in Modern Neurointensive Care

Current clinical practice guidelines from major international stroke societies do not recommend routine prophylactic hypermagnesemia in patients with acute aneurysmal subarachnoid hemorrhage. Specifically, the American Heart Association and Neurocritical Care Society emphasize that enteral nimodipine remains the singular pharmacological agent proven to reduce delayed cerebral ischemia and improve functional outcomes. Therefore, intensivists should maintain oral nimodipine at standard dosages of 60 mg every four hours for 21 days unless dose-limiting hypotension supervenes.

Nevertheless, vigilant electrolyte management remains a fundamental cornerstone of neurocritical care. Subarachnoid hemorrhage frequently triggers severe systemic disturbances, including hypomagnesemia, hyponatremia, and hypokalemia due to sympathetic overdrive and renal wasting. Because hypomagnesemia exacerbates cerebral arterial irritability and increases cardiac arrhythmia risks, clinicians must aggressively replate deficient patients back to physiological baselines. In addition, neurocritical care units should maintain euvolemia, optimize cerebral perfusion pressure, and conduct systematic surveillance using serial neurological assessments and transcranial Doppler imaging. If delayed neurological deficits emerge, clinicians should promptly initiate induced hypertension and consider rescue endovascular intervention rather than relying on unproven infusions. Overall, structured multidisciplinary care pathways ensure balanced physiological stabilization without exposing patients to ineffective prophylactic treatments.

Frequently Asked Questions

Does magnesium therapy reduce delayed cerebral ischemia after aneurysmal SAH?

Current randomized controlled trials indicate that routine intravenous magnesium infusions do not significantly reduce delayed cerebral ischemia or improve functional outcomes. Although magnesium can attenuate hemodynamic flow velocities on transcranial Doppler, this arterial effect fails to prevent microvascular thrombosis, cortical spreading depolarizations, and downstream neurological deficits in clinical practice.

What serum magnesium concentration showed benefits in exploratory analyses?

In exploratory multivariable analyses, maintaining a median serum magnesium concentration of at least 2.5 mg/dL during the initial 14 hospital days was independently associated with reduced risks of cerebral vasospasm and delayed cerebral ischemia. However, because these secondary findings remain purely hypothesis-generating, clinicians should not adopt high-dose prophylactic infusions routinely.

What is the guideline-recommended medical therapy to prevent delayed cerebral ischemia?

International neurocritical care guidelines strongly recommend oral nimodipine administered at 60 mg every four hours for 21 consecutive days as standard evidence-based medical prophylaxis. Clinicians should maintain strict normovolemia, avoid routine prophylactic hypermagnesemia, and promptly correct systemic hypomagnesemia or electrolyte derangements to prevent cardiac arrhythmias and vascular instability.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Kim M et al. Magnesium administration for vasospasm prevention in acute aneurysmal SAH: a multicenter randomized controlled trial. Neurosurg Rev. 2026 Sep 08. doi: 10.1007/s10143-026-04470-z. PMID: 42709254.
2. Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380(9836):44-49.
3. Wong GKC, Poon WS, Chan MTV, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41(5):921-926.
4. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314-e370.